

ArchimicaCorporate Presentation

Strong. Steady. Focused on Technology.





Archimica at a Glance - Strengths

Vast Experience with the Most Challenging Reagents, Reactions and Substance Classes Known.



Made in Europe



Premium Client Attention



Agile Capacity Availability



Experienced, flexible Technology Transfer, Development and Engineering Team



Highly Flexible Manufacturing and Development





Profile

APIs/GMP Building Blocks - Process Development and Manufacturing. From Clinical to Large Commercial Scale for the Innovative and Generic Industry.

Products

APIs.

Active Pharmaceutical Ingredients.

GMP/non-GMP Building Blocks.

Capacities

Typically:

1 to 600 mt annually.

Batch Size 25-2500 kg. synthesis steps 1-8.

Specifically:

2 to 300 mt annually.

Batch Size 50-1500 kg. Synthesis Steps 2-5.

Kilo lab

1-200 Kg annually

Batch size - 1 - 10 kg Synthesis steps 2-5

Portfolio

Products.

Generic API Portfolio.

Services.

Custom Development and Manufacturing.

Broad Range of Substance/Therapeutic Classes.

Regulatory/Quality

Track Record of Successful Agency Inspections.

FDA (2017), AIFA (2024).

Broad Scope.

Highly Flexible Permit.
State-of-the-Art Environmental Protection.

Technology/Differentiators

Small Molecules.

Up to OEB4 Potency Level.

Vast Range of the Most Challenging Reagents and Reactions on Industrial Scale.

Company

Global Supply.

More than 50 Countries Actively Supplied.

Backed by Prime Independent Investor.





Market Presence

Customers are relying on Archimica's Products and Services for Quality Medicine Worldwide.

All Therapeutic Classes
All Substance Classes (including Anticancer APIs)

7 Active Products
24 Active Drug Master Files in 39 Countries
200 Active Customers
Supplying more than 50 Countries Worldwide

SAPTM-ERP System







Site Overview

500 L - Scale up/filing products

Highly Flexible, Efficient, Experienced GMP Site - Located in Lodi, Italy, close to Milano

Plant Staff Total Reactor Volume: 250 m³ Total Staff Number: 116 170 m³ Multi-Purpose 55% Production APIs and GMP intermediates $50 \, \mathrm{m}^3$ 25% Quality Large-Volume Product 30 m^3 10% Engineering & Maintenance **Anticancer Products** Kilo Lab 10% Sales & Administration





Manufacturing Overview

Reactor Capacity Supported by a Vast Range of Sophisticated Ancillary Technology

Reactor Capacity



Highly Flexible Multi-Purpose Capacity. Various Materials of Construction.

Stainless Steel - Glass Line - Glass - Hastelloy - Monel - Various.

Temperature Range: -20 to 160°C. Pressure Range: 10 mbar to 6 bar.

Reactor Volume Range: 50 to 10.000 liters.

Centrifuges/Filters



Filters:

Filter Presses - Filter Dryers - Pressure Filters

Centrifuges:

Vertical Axis Top Discharge - Vertical Axis Bottom Discharge - Horizontal Axis Peeler

Dryers



Fluid Bed - Agitated Vacuum Pan - Vacuum Horizontal Agitated - Vacuum Double Cone - PlanexTM - Tray

Kilo Lab



Capable of handling: 1 to 10kg batch size
Three stages of manufacturing Glass Radley reactors; SS reactors Filtration & drying Powder processing

Ancillary Equipment



Sieves - Ultra Filters - Ion Exchange Chromatography Columns





Multi-Purpose Capabilities - Broad and Flexible

Seamless from 100 gm to 100 mt-Scale - APIs and GMP Intermediates.

Scale	1-10 kg	>10-250 kg	> 1-5 mt	> 5-20 mt	> 5-100 mt	> 10-100 mt	0,1-100 mt
Plant	F5	F2B	F5B	F6B	F 7	> F2A	F3B Drying
Reactor Size	0,05-0,1 m ³	0,2-0,8 m ³	3,0-4,9 m ³	3,4-10 m ³	0,7-6,6 m ³	0,8-9,7 m ³	0,1-1 m ³
Temperature Range	-20/120°C		-10/145°C				
Equipment	Reactors Distillation Pressure Filters		Fluid Bed, Double Cone Various				
Construction Materials	Stainless Steel Glass Line	Stainless Steel Hastelloy Monel	Stainless Steel Glass Line				
Volume Total: 170 m ³	0,25 m ³	2,75 m³	15 m³	20 m³	60 m ³	72 m³	Volume Total 5,5 m ³





Therapeutic Areas and Substance Classes

Supporting Active Pharmaceutical Ingredient Supply for All Applications.

Therapeutic Areas



Anthrachinones

Benzodiazepinones

Benzophenones

Dibenzazepines

Fluorouracils

Heterocyclic Acidic Acids

Heterotricyclics

Nitroimidazoles

Nucleoside Analogues

Organometallic Complexes

Phospholipids, deacylated

Phtalazines

Purine Analogues

Pyrrole Derivates

Sucrose Sulfates/Complexes

Sulfanilamides

Sulfonamides

Tetrazoles, Mono/Bicyclic

Ureas

Substance Classes



Anti-Alzheimer, Cognition Enhancers

Antiacidics, Antiulcers

Antiarrhythmics

Anticancers, Cytostatics

Anticonvulsants

Antidepressives/Anti-Epileptics

Anti-Bipolar Disorders

Antihistaminics, Antiallergics Antihypertensives/Vasodilators

Antiinfectives

Antiinflammatories

Antiobesities

Immunosuppressives





Reactions, Reagents and Solvents

Practically unlimited capability to perform/use the most challenging reactions, reagents and solvents on small, medium and large industrial scale under GMP - a few examples.

Reagents/Reactions





1-500 mt/a

SO₃·Py (sulfur trioxide/pyridine)

CISO₃H (chlorosulfonic acid)

CrO₃ (chromium trioxide)

Ac₂O (acetic anhydride)

HOAc (acetic acid)

Py (pyridine)

AlCl₃ (aluminium chloride)

POCl₃ (phosphorous

oxychloride)

1-100 mt/a

NH₂OH (hydroxylamine) NaOCN (sodium cyanate)

Natural source materials

(lecithin, aloine)

1-20 mt/a

N₂H₄ (hydrazine)

NH₃ (ammonia)

HCHO (acetaldehyde)

HCOOH (formic acid)

HF/HCI/HBr (hydrogen halides)

KCN (potassium cyanide)

CH₃N (trimethylamine)

F₂/Cl₂/Br₂ (halogen gases)

H₂ (hydrogen)

CH₂O (ethylene oxide)

Styrene oxide

Dess-Martin Periodinane

R-SO₂CI (sulfonyl chlorides)

Ag/Au/Cu-salts (precious metals)

1-500 mt/a

Solvents

Dimethylacetamide

Ethanol

Acetone

Cyclohexane

Isopropanol

Methanol

1-100 mt/a

Methylene chloride

1,2-Dichloropropane

Tetrachloromethane

Dimethylformamide





Generic API Portfolio

Archimica Continuous API Supply Worldwide.

Active Pharmaceutical Ingredients (APIs)



Anticancer

Cytarabine (nucleoside analogue) - CEP Hydroxyurea (modified urea) - CEP

Antipsychotic

Mianserin (tetracyclic) – CEP

Antiacidic/Antiulcer

Sucralfate (saccharose sulfate)

Antiinfective

Sulfathiazole (sulfonamide)

Antiulcers

Sucrose octasulfate potassium salt (KSOS) –non-API grade

Anti-Alzheimer/Cognition Enhancer

Glycerophosphoryl-Choline (GPC) – technical grade Glycerophosphorylethanolamine (GPE) – technical grade





Generic API Portfolio

Archimica Continuous API Supply Worldwide.

Products on Request - Active Pharmaceutical Ingredients (APIs)



More than additional 20 Active Pharmaceutical Ingredients (APIs) available from Archimica's Experience - including Customer-Specific Development - a selection

Bromfenac - EUDMF/USDMF

Capecitabine - EUDMF/USDMF

Citicoline – EUDMF

Dihydralazine sulfate – EUDMF

Disopyramide – EUDMF

Hydralazine hydrochloride – EUDMF/USDMF

Lithium Carbonate - EUDMF/USDMF

Pirenzepine Dihydrochloride - EUDMF/USDMF

Sulfapyridine – EUDMF/USDMF

Thenfadil – EUDMF

Tolmetin – EUDMF

Oxcarbazepine (dibenzazepine) – EUDMF/USDMF





Quality System, Inspections, Certificates

Sucessfully Inspected and Accepted Worldwide.

Quality System



Inspections



Certificates



Quality System Based on EU GMP part II, ICH Q7.

Quality Processes Handled via Trackwise[™].

Deviations, Out-of-Specifications (OOS), CAPA, Change Control.

US/EU Drug Master Files.

24 Active Drug Master Files in 39 Countries and 4 active CEP.

FDA (USA).

Last Inspection April 2017.

AIFA (Italy).

Last Inspection October 2024.

KFDA (Korea).

Last Inspection October 2011.

Veterinary Ministry of Health. Last Inspection November 2024.

GMP Certificate (Human).

IT-API/1H/2025

GMP Certificate (Veterinary).

NBF/3/2025/V

FFI Number

3002874947

DUNS Number.

429351620





Infrastructure - Operating Permits

Integrated Responsibility for Environment, Health and Safety.

Environment & Health



Safety



Residual Thermal Oxidizer.

All Waste Gas Streams.

Wastewater Treatment on Site.

Backed by External Partners.

Solvent Recovery.

Backed by Flexible Tank Farms.

IPPC-based Authorization.

Integrated Pollution Prevention and Control.

Highly flexible and broad permit for all technologies, reagents and solvents.

Compliance with IED Directive 2010/75/UE.

Best Available Technology.

Compliance with Directive 105/15 2012/18/EU.

Seveso Directive.

Prevention and Control of On-Shore Major Accident Hazards involving Dangerous Substances.





History

Archimica's Evolution - 77 Years of Continuity of Supply into the World's Pharmaceutical Market.

Foundation	Maradavia				
of Prime European Therapeuticals	Mandarin Capital Partners becomes Majority	Clessidra, an Italian Financial Fund becomes Majority	AMRI acquires Euticals Group	Livia acquires Lodi Site, it becomes Archimica	PI HEALTH SCIENCES Acquires Archimica S.p.A
0.61. ((2000.0)	Euticals Shareholder	Euticals Shareholder		LIVIA I NTERNATIONAL VENTURES & INVESTMENT ACTIVITIES	Health Sciences
	European	European Partners Therapeuticals becomes S.p.A (Euticals) Majority Euticals	European Partners Financial Therapeuticals becomes S.p.A (Euticals) Majority Majority Euticals Euticals	European Partners Financial Euticals Therapeuticals becomes Fund becomes Group S.p.A (Euticals) Majority Majority Euticals Euticals	European Partners Financial Euticals becomes Therapeuticals becomes Fund becomes Group Archimica S.p.A (Euticals) Majority Majority Euticals Euticals Shareholder Shareholder



Contacts



www.archimica.com



contact@archimica.com



Archimica S.p.A



+39 0371 4902356



